EMA Application withdrawn: Prohippur (sodium benzoate) — Lucane Pharma

View source ↗

Summary

The EMA withdrawed the application for Prohippur (sodium benzoate) by Lucane Pharma for urea cycle disorders and hyperglycinemia, nonketotic.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperglycinemia Nonketotic
• Urea Cycle Disorders Inborn

Drugs mentioned

• Prohippur (sodium benzoate)

Snippet

Status: Application withdrawn. Therapeutic area: Urea Cycle Disorders, Inborn;Hyperglycinemia, Nonketotic. MAH: Lucane Pharma. Decision date: 27/04/2018. Orphan medicine